Renin-angiotensin system inhibitors + SGLT2 inhibitors + GLP-1 receptor agonists

Renin-angiotensin system inhibitors + SGLT2 inhibitors + GLP-1 receptor agonists decrease mortality in silico (2-fold).

In silicoin individuals with diabetes, microsimulation projection vs dual-therapyn = 8,152

A Microsimulation of Eligibility for Cardiorenal Combination Treatment and Potential Deaths Averted

Journal of the American Society of Nephrology : JASN·9 Oct 2026